NeuroSense Therapeutics satisfies Nasdaq's minimum bid price rule while seeking a hearing to address ongoing market value compliance requirements.
NeuroSense regained compliance with Nasdaq's minimum bid price requirement but still needs to address the minimum market value requirement, with a hearing requested.
NeuroSense Therapeutics Ltd. has successfully regained compliance with Nasdaq's minimum bid price requirement. The company now shifts its focus to the minimum market value requirement and plans to request a hearing with the Nasdaq Hearings Panel to secure additional time for full regulatory alignment.
NeuroSense has regained compliance with the minimum bid price requirement but remains non-compliant with the minimum market value requirement.